Publications by authors named "Vivek A Upadhyay"

Claim this Profile
R
Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort.
Vivek A Upadhyay, Bruce E Johnson, Adam B Landman, Michael J Hassett

JCO Precis Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
Karthikeyan Murugesan, Radwa Sharaf, Meagan Montesion, Jay A Moore, James Pao, Vivek A Upadhyay

JCO Precis Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Landscape Analysis of Oncology Mobile Health Applications.
Vivek A Upadhyay, Adam B Landman, Michael J Hassett

JCO Clin Cancer Inform· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative.
Vivek A Upadhyay, Benjamin P Geisler, Lova Sun, Lynne Uhl, Richard M Kaufman

Br J Haematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
Justin Taylor, Michael Haddadin, Vivek A Upadhyay, Erwin Grussie, Neha Mehta-Shah

Blood· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura.
Lova Sun, Johnathan Mack, Ang Li, Justine Ryu, Vivek A Upadhyay

Blood Adv· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy in acute myeloid leukaemia: origins and emerging directions.
Vivek A Upadhyay, Amir T Fathi

Curr Opin Hematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
Vivek A Upadhyay, Andrew M Brunner, Amir T Fathi

Pharmacol Ther· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.
Victor D Fedorov, Vivek A Upadhyay, Amir T Fathi

Curr Hematol Malig Rep· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis